Transcriptomics

Dataset Information

0

LncRNA AGPG confers endocrine resistance in breast cancer by promoting E2F1 activity


ABSTRACT: Resistance to endocrine therapy represents a major threat to patients with estrogen receptor α positive (ERα+) breast cancer. The development of resistance is mainly through activating E2F signaling. However, the mechanisms that govern E2F1 activity in these resistant cells remain poorly understood. Here, we identify Actin Gamma 1 Pseudogene 25 (AGPG) as a lncRNA whose expression is driven by epigenomic activation of enhancer in endocrine resistant breast cancer cells. High expression of AGPG is associated with poor survival of ERα+ breast cancer, especially in patients receiving endocrine therapy. Stable knockdown and overexpression of AGPG demonstrate that AGPG promotes endocrine resistance, cell cycle progression, cell proliferation in vitro and in vivo. AGPG functions by direct binding purine rich element binding protein α (PURα), a transcription factor repressing E2F1 signaling and sensitized ERα+ breast cancer cells to endocrine therapy. Via binding to the region responsible for PURα/E2F1 interaction in PURα protein, AGPG releases E2F1 from PURα, leading to activation of E2F1 signaling in ERα+ breast cancer cells. Clinically, E2F1 target genes are strongly correlated with AGPG and PURα expression. Thus, our study reveals AGPG as a promising biomarker and potential therapeutic target in breast cancer.

ORGANISM(S): Homo sapiens

PROVIDER: GSE218130 | GEO | 2023/07/12

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2022-08-12 | PXD026864 | Pride
2013-05-01 | E-GEOD-37323 | biostudies-arrayexpress
2019-02-09 | PXD010314 | Pride
2010-09-01 | E-GEOD-20361 | biostudies-arrayexpress
2015-12-12 | GSE73320 | GEO
2015-12-31 | GSE60517 | GEO
2010-12-29 | GSE26081 | GEO
2022-03-14 | GSE190095 | GEO
2013-05-01 | GSE37323 | GEO
2022-10-06 | GSE111914 | GEO